Quantcast
Last updated on April 24, 2014 at 12:23 EDT

Latest Antigen Express Inc. Stories

2013-05-22 08:29:34

Studies show superiority of AE37 among peptide cancer vaccines WORCESTER, Mass. and TORONTO, May 22, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced three presentations demonstrating the superiority of the AE37 breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The presentations will be made at the annual meeting of the American Society of Clinical Oncology (ASCO)...

2013-02-07 12:27:11

WORCESTER, Mass. and TORONTO, Feb. 7, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today provided an overview of the current pipeline and potential of its wholly-owned subsidiary Antigen Express, Inc. (www.antigenexpress.com). While the Company is currently in a late Phase IIb trial of a very promising new immunotherapy for early breast cancer (AE37), the Company has made concrete headway in demonstrating a robust pipeline for AE37 indications beyond...

2013-01-31 08:30:54

WORCESTER, Mass. and TORONTO, Jan. 31, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today explained the potential of the technology platform used as the basis for its novel breast cancer immunotherapy product AE37. AE37 is currently in late Phase IIb clinical development and has garnered considerable attention based upon favourable results from interim analysis of its controlled, randomized, and blinded trial in women with early stage breast cancer....

2013-01-30 12:26:35

WORCESTER, Mass. and TORONTO, Jan. 30, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today provided an overview on the early breast cancer competitive status of the lead cancer immunotherapy product, AE37, under development at its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). A detailed update on development plans will be provided during the previously announced conference call scheduled for Thursday, January 31, 2013....

2013-01-29 12:27:06

WORCESTER, Mass. and TORONTO, Jan. 29, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) previously announced that Company management has scheduled an investor conference call for Thursday, January 31, 2013. Today, the Company provided the following information for access to the conference call: <blockquote> Date of Call: Thursday, January 31, 2013 Time of Call: 10 a.m. EST Participant Operator Assisted Toll-Free Dial-In Number: (877)...

2013-01-11 08:22:02

WORCESTER, Mass. and TORONTO, Jan. 11, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) today announced that Company management has scheduled an investor conference call for Thursday, January 31, 2013. The purpose of the call is to provide the Company's stockholders with a review of recent Company activity and management's go-forward plans. The discussion will include: the clinical and regulatory status of the AE37 breast cancer vaccine and business development...

2012-11-13 08:36:10

WORCESTER, Mass. and TORONTO, Nov. 13, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) today provided the following update on company initiatives. Antigen Express, Inc. (www.antigenexpress.com), a wholly-owned subsidiary of Generex, is in late Phase II clinical development of a novel immunotherapeutic for breast cancer (AE37) that demonstrates promising trends in preventing relapse. The interim results of the large, controlled, randomized, and single blinded trial were...

2012-09-20 06:30:39

WORCESTER, Mass. and TORONTO, Sept. 20, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) (www.generex.com) today released the following letter to its stockholders. To the Stockholders of Generex Biotechnology Corporation: The purpose of this letter is to provide the Generex Biotechnology Corporation stockholders with an update on Company initiatives and a review of Company operations over the past year. (a) Antigen Express The clinical and regulatory program...

2012-09-13 02:28:19

WORCESTER, Mass. and TORONTO, Sept. 13, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) (www.generex.com), announced today presentation of early results from an efficacy study of an immunotherapeutic in triple negative breast cancer patients. The immunotherapeutic is being developed by Antigen Express, Inc. (www.antigenexpress.com), a wholly owned subsidiary of Generex. The results will be presented on Friday, September 14, 2012 at the 2012 Breast Cancer...

2012-09-12 06:31:57

WORCESTER, Mass. and TORONTO, Sept. 12, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) today addressed the unusual high volume of trading in shares of its common stock on the Over-the-Counter Bulletin Board yesterday and today. The trading did not involve any shares held by current Company officers, directors, insiders, or employees. Generex management is not aware of any Company developments that might tend to precipitate the unusual and sudden trading activity seen...